| Clinical data | |
|---|---|
| Other names | CT868; RG-6641; RG6641 |
| Routes of administration | Subcutaneous injection[1] |
| Drug class | GLP-1 receptor agonist; GIP receptor agonist; Antidiabetic agent; Anti-obesity agent |
CT-868 is an experimental "biased dual GLP-1 and GIP receptor modulator that exhibits no arrestin coupling or receptor internalization at either receptor". It is developed by Carmot Therapeutics for diabetes and obesity. The drug is taken by subcutaneous injection.[1][2][3][4]
References
- "CT 868". AdisInsight. 7 August 2025. Retrieved 4 April 2026.
- Chakravarthy MV, Elliott MA, Acosta L, Sonnenberg GE, Bialonczyk D, Wu J, Argüelles-Tello FA, Garcia-Reza R, González-González JG, Hansen SK, Frias JP (March 2026). "Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial". Diabetes Obes Metab. 28 (3): 1673–1682. doi:10.1111/dom.70006. PMC 12890765. PMID 40762050.
- Chakravarthy, Manu; Hernandez, Moises; Elliott, Michael; Macias, Alejandra; Hansen, Stig K.; Hompesch, Marcus (20 June 2023). "774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes". Diabetes. 72 (Supplement_1). doi:10.2337/db23-774-P. S2CID 259219222.
- Rodriguez, Ruben; Tracy, Ted; Morales, Marikris; Hergarden, Anne; Lam, Davina; Krishnan, Shyam; Hansen, Stig K.; Chakravarthy, Manu (20 June 2023). "1649-P: Biased GLP-1 Improves Weight Loss with Additional Benefits on Glucose Homeostasis via Biased GIP in Diabetic Rodent Models". Diabetes. 72 (Supplement_1). doi:10.2337/db23-1649-P. S2CID 259427049.